FDA issues warning letter to Amazon for selling unapproved eye care products


This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

©michelangeloop / Adobe.stock.com

Image Credit: ©michelangeloop / Adobe.stock.com

In a letter addressed to Andrew Jassy, President and CEO of Amazon, the US Food and Drug Administration (FDA) issued a warning to the company regarding the sale of unapproved ophthalmic drugs.

Recently, the FDA urged customers to avoid a slew of eyedrops due to the possible risk of eye infections that could result in vision loss or blindness. This is just one of many times the FDA has issued a warning on unapproved ophthalmic products in 2023.

The letter specifies 7 drugs that Amazon is “responsible for introducing or delivering for introduction into interstate commerce” which are “unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”), 21 U.S.C. 355(a).” Furthermore, the letter states that the introduction of these products into interstate commerce is “prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).”

The list of ophthalmic drops included in the letter are:

  • Similasan Pink Eye Relief
  • The Goodbye Company Pink Eye
  • Can-C Eye Drops
  • Optique 1 Eye Drops
  • OcluMed Eye Drops
  • TRP Natural Eyes Floaters Relief
  • Manzanilla Sophia Chamomile Herbal Eye Drops

In the letter, the FDA warns Amazon that these products are especially concerning because “ophthalmic drug products, which are intended for administration into the eyes, in general, pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.”

The listed drops are not generally recognized as safe and effective (GRASE) for their listed uses, says the FDA. The FDA defines these drugs as “new drugs,” and new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from the FDA (with certain exceptions).

The FDA warned Amazon that action must be taken within 15 working days of receiving the letter at risk of legal action. The FDA also requested “an explanation of each step being taken to prevent the recurrence of violations, including steps [Amazon] will take to ensure that [it] will no longer introduce, deliver, or cause the introduction or delivery into interstate commerce of, ophthalmic unapproved new drug products, as well as copies of related documentation.”1

As of writing all of the products listed in the warning letter have been removed from Amazon and are unable to purchase.

  1. Warning letter to Amazon. Released November 13, 2023. Accessed November 16, 2023. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazoncom-inc-665460-11132023
Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.